Four hundred ninety-seven DM patients who received mesenchymal stem cells, showed significantly improved pathological factors (including HbA1c, blood glucose level, c-peptide, and insulin requirement) in 3 to 12 months. This evidence concerns the gene INS and diabetes mellitus.